share_log
Reuters ·  Apr 30 09:00
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination With Pembrolizumab in Patients With Untreated Hpv-Mediated Oropharyngeal Cancer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment